Renal Cell Carcinoma Clinical Trials in Pittsburgh, Pennsylvania

5 studies are recruiting for renal cell carcinoma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

   Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participant…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   UPMC Cancer Center/Hillman Cancer Center ( Site 5017), Pittsburgh, Pennsylvania

   Locations

   32 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07049926 on ClinicalTrials.gov

2. Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

   This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   13 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04981509 on ClinicalTrials.gov

3. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Pittsburgh, Pennsylvania

   Locations

   13 in total

   Run by

   AstraZeneca

   See if you can join NCT07115043 on ClinicalTrials.gov

4. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

   The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Diwakar Davar

   See if you can join NCT07223424 on ClinicalTrials.gov

5. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC- Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov